Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
CytoDyn logo — CytoDyn’s purpose is to help enhance the lives of patients w...

CytoDyn

CytoDyn’s purpose is to help enhance the lives of patients with life-threatening diseases.

Founded 2002 United States Vancouver, United States 21 employees Post-IPO Equity Biotechnology, Health and Wellness +1

General Information

Company Name CytoDyn
Founded Year 2002
Location United States Vancouver, United States
Founders / Decision Makers
Team member Team member Team member Team member Team member Team member
Employees 21
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with CytoDyn. To contact CytoDyn, visit cytodyn.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CytoDyn compare?

A PDF of CytoDyn and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CytoDyn soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CytoDyn

CytoDyn is a biotechnology company dedicated to enhancing the lives of patients with life-threatening diseases. The company is currently in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. Leronlimab, a humanized monoclonal antibody, is administered as a once-a-week subcutaneous injection and can also be given intravenously. It competitively binds to the CCR5 receptor, setting it apart from other CCR5 antagonists.

Established in 2002, CytoDyn operates in the biotechnology, health and wellness, and pharmaceutical industries. The company recently secured a Post-IPO Equity investment on 15 September 2021, indicating ongoing support and interest in its groundbreaking work. The specific details of this investment, including the amount and the involved investors, have not been disclosed.

Business keywords: Pharmaceuticals, HIV/AIDS, Clinical Development, Therapeutic Anti-Viral Agents, Monoclonal Antibodies, Immune Deficiency Diseases, CCR5 Antagonists, Oncology, NASH, Metastatic Triple-Negative Breast Cancer, Medical Research, Infectious Diseases, Therapeutic Indications, Drug Development

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
15 Sep 2021
Post IPO Debt Undisclosed -
31 Mar 2020
Post IPO Equity Undisclosed -
11 May 2016
Post IPO Equity Undisclosed -
23 Feb 2016
Post IPO Equity Undisclosed -
05 Oct 2015
Post IPO Debt Undisclosed -
14 May 2015
Post IPO Equity Undisclosed -
25 Sep 2013
Post IPO Debt Undisclosed -
12 Aug 2013
Post IPO Equity Undisclosed -
15 Feb 2013
Post IPO Equity Undisclosed -
07 Dec 2011

View All 11 Funding Rounds

CytoDyn Alternatives & Competitors

View All Alternatives
CytoDyn vs
Phoenix Molecular Designs
Phoenix Molecular Designs United States

A clinical stage biopharmaceutical company designing precise cancer therapeutics to address unmet me...

Series A
22 employees
Biotechnology, Health Care
CytoDyn vs
Arcus Biosciences
Arcus Biosciences United States

Global, biopharmaceutical company at the forefront of designing precision combinations in the pursui...

IPO
646 employees
Biopharma, Biotechnology
CytoDyn vs
Senex Biotechnology. Inc.
Senex Biotechnology. Inc.

Preventing Adaptive Drug Resistance and Cancer Metastasis

Debt Financing
5 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About CytoDyn

CytoDyn’s purpose is to help enhance the lives of patients with life-threatening diseases.
CytoDyn was founded in 2002.
CytoDyn is headquartered in Vancouver, United States.
CytoDyn operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Pharmaceuticals, HIV/AIDS, Clinical Development and Therapeutic Anti-Viral Agents.
CytoDyn has approximately 21 employees.
CytoDyn has completed 11 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to CytoDyn include Phoenix Molecular Designs, Arcus Biosciences, Senex Biotechnology. Inc., Antharis Therapeutics, Inc., KALSIOM SAS. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CytoDyn and Phoenix Molecular Designs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CytoDyn, https://bouncewatch.com/company/cytodyn, updated 6 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes